Abstracts

2020 – Phase I/II Study Of Radiation Enhancing Hafnium Oxide Nanoparticles NBTXR3 Activated by SBRT in HCC and Liver Metastases Patients

Abstracts, Donnée clinique de NBTXR3, Foie

Stereotactic body radiotherapy (SBRT) is a well-tolerated and valuable alternative for patients with unresectable hepatocellular carcinoma (HCC) or liver metastases (mets) who are not eligible for standard treatment such as surgery, local ablation or chemoembolization. […]

Continuer la lecture…

2020 – NBTXR3 radiation enhancing hafnium oxide nanoparticles: RP2D for the treatment of HCC and liver metastases

Abstracts, Donnée clinique de NBTXR3, Foie

NBTXR3, functionalized hafnium oxide nanoparticles, administered by intratumoral injection (ITI) and activated by radiotherapy (RT), such as stereotactic body RT (SBRT), increases energy deposit inside tumor cells and subsequently tumor cell death compared to RT alone, while sparing healthy tissues. This innovative approach, which does not engage liver and renal functions, might benefit patients (pts) with unresectable liver cancers. […]

Continuer la lecture…

2020 – NBTXR3 Radiation Enhancing Hafnium Oxide Nanoparticles Activated By Radiotherapy In Cisplatin-Ineligible Patients With Locally Advanced HNSCC: A Phase I Trial

Abstracts, Donnée clinique de NBTXR3, NO-RIGHTS, Tête & Cou

Concurrent chemoradiation (CRT) with high dose cisplatin or cetuximab in case of contra-indication to cisplatin is the standard of care non-surgical approach for patients (pts) with locally advanced head and neck squamous cell carcinoma (LA HNSCC). […]

Continuer la lecture…

2020 – Phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with an anti-PD-1 therapy

Abstracts, Donnée clinique de NBTXR3, Foie, NO-RIGHTS, Poumon, Tête & Cou

Despite the past decade of transformative advances in immuno-oncology, the response rate to checkpoint inhibitors (ICIs) remains low (~15%). There is significant interest in developing strategies to overcome resistance to these treatments, thus increasing response rate. Emerging evidence suggests that radiation therapy (RT) could potentially augment the antitumor response to ICIs through synergic effect. […]

Continuer la lecture…

2020 – Phase I trial of hafnium oxide nanoparticles activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients

Abstracts, Donnée clinique de NBTXR3, NO-RIGHTS, Tête & Cou

The standard of care non-surgical approach for locally advanced head and neck squamous cell carcinoma (LA HNSCC) patients (pts) is concurrent chemoradiation with high dose cisplatin or cetuximab in case of contra-indication. Older age is a contra-indication to cisplatin, and cetuximab might not improve survival in older pts. […]

Continuer la lecture…

2020 – Hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy for the treatment of frail and/or elderly patients with locally advanced HNSCC: a phase I/II study

Abstracts, Donnée clinique de NBTXR3, NO-RIGHTS, Tête & Cou

Elderly and/or frail patients (pts) with head and neck squamous cell carcinoma (HSNCC) remain a challenging to manage and neglected population regarding clinical trials and data generation to support treatment choices. Despite representing 20% of the HNSCC population no consensus exists on what is the optimal treatment for these pts with locally advanced (LA) disease, vulnerable to treatment-induced toxicities with the current standard of care. […]

Continuer la lecture…

2020 – Treatment of hepatocellular carcinoma and liver metastases with hafnium oxide nanoparticles activated by SBRT: a phase I/II trial

Abstracts, Donnée clinique de NBTXR3, Foie

Treatment of unresectable liver cancer or liver metastases (mets) by stereotactic body radiotherapy is well tolerated but limited by the need to preserve liver function. Increasing energy deposition in the tumor while at the same time maintaining the dose in healthy tissue remains a major challenge in radiation oncology that could be achieved by NBTXR3 (hafnium oxide nanoparticles) when activated by radiotherapy (RT). […]

Continuer la lecture…

2020 – SITC – NBTXR3 Generates Long Term Immune Memory

Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Although treatment of high-dose (HD) radiation (XRT) and NBTXR3 (R3) on primary tumors in combination with systemic anti-PD1 was able to significantly improve abscopal effect in 344SQR murine metastatic lung cancer, most of the mice eventually expired due to the growth of metastatic tumors. Therefore, we studied the effects of R3 injection into primary tumors plus high-dose radiation on primary tumor and low-dose raditionon metastatic tumor plus dual-agent immunotherapy (IT) of anti-PD1 and anti-CTLA-4 to achive complete control of tumor growth at both the primary and the metastatic tumors in mice. […]

Continuer la lecture…

2020 – SITC – TCR Repertoire

Abstracts, In Vitro in Vivo NBTXR3, In Vivo

For decades, radiotherapy (RT) has been a cornerstone of cancer treatment. Currently, approximately 50% of cancer patients will be treated with RT. Beyond the ability of RT to produce free radicals and to generate single and double-strand breaks in DNA, triggering cell death, preclinical and clinical studies have demonstrated that RT can have immunomodulatory effects. For example, RT can stimulate MHC class I expression on cancer cells, induce immunogenic cell death (ICD), and activate expression of various pro- and anti-inflammatory cytokines and adhesion molecules, allowing recruitment and activation of both innate and adaptive immune cells into the tumor. […]

Continuer la lecture…

2020 – ESTRO – NBTXR3 for the Treatment of Advanced Liver Cancers

Abstracts, Donnée clinique de NBTXR3, Foie

The use of stereotactic body radiotherapy (SBRT) for the local control of unresectable hepatocellular carcinoma (HCC) or liver metastases (mets) is well tolerated but limited by the need to preserve liver function. Increasing energy deposit within the tumor without increasing toxicity in healthy tissues remains a major challenge in radiation oncology. NBTXR3 (hafnium oxide nanoparticles), a first-in-class radioenhancer when activated by RT augments energy dose deposit within tumor cells, increasing tumor cell death compared to RT alone, while sparing healthy tissues. […]

Continuer la lecture…

Les congrès sont clés pour Nanobiotix, lors de ces évènements, la Société publie des données et des résultats scientifiques. Cette section répertorie les abstracts qui ont été acceptés et publiés par Nanobiotix au cours de la dernière décennie.